| Description | Emicizumab(ACE 910) is a humanized monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A. It has been shown to be effective in the treatment of hemophilia A. It has been shown to be effective in the prevention and treatment of hemophilia A. |
| In vivo | Emicizumab（1.5-10 mg/kg；静脉注射；在尾部剪切出血测试前24小时）在一种具有FVIII等效值9 U/dL的A型血友病出血模型中部分纠正了血液丧失。[1] 当与低剂量FVIII（10 U/dL）联合使用时，Emicizumab（3 mg/kg；静脉注射）提供了额外的止血活性。[1] |
| Synonyms | ACE 910, RO 5534262 |
| molecular weight | N/A |
| CAS | 1610943-06-0 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748. |